Corporate Training · New for 2026

AI-Enabled Commercial Analytics & Automation: Build It Yourself, with AI

Your analysts do not need another BI license. They need to build: pricing analytics, commercial insights, and the automations that eliminate the manual work between them. This program teaches your team to do exactly that with Claude and OpenAI, using the same AI tools and workflows Revology runs its own practice on.

Pharmaceutical price optimization is only as defensible as the data assembly underneath it. Revology, the #1-ranked Pricing & RGM consultancy for mid-market companies, co-designs PRISM inside your commercial team: DDD-equivalized competitive pricing, a Right-to-Price worth model, price-pack architecture, and causal elasticity using Double Machine Learning, all on one governed, reproducible engine that traces every recommendation back to its inputs. AI is an enabler here, not the product. The work stays scoped to pricing and revenue decisions.

Pharma pricing leaders own a workbook they quietly mistrust.

The mistrust is rational. The workbook sits at the wrong end of four data pain points specific to pharma:

List price and channel rebate accruals scattered across the ERP, finance trackers, and CRM.
An IQVIA competitive view with its own naming conventions and pack-size codes, joined through a tab full of VLOOKUPs.
Like-for-like SKU matching (molecule, strength, form, route, pack size, release flag) treated as a senior analyst’s hand exercise.
Defined Daily Dose (DDD) assignment done manually for your own brands and skipped for competitors.

Each pain point compounds the moment you cross three or four markets. And a delayed price move, in most markets, is itself a price decision: the price holds while inflation runs and a competitor takes the position.

What it is

Four modules, one engine

DDD-Equivalized Competitive Pricing

Where am I mispositioned?

It automates the like-for-like join and reads the competitive gap at the only honest layer: price per Defined Daily Dose, not pack price.

Right-to-Price (R2P)

Where is my worth underpriced?

It scores brand worth and surfaces where realized price sits below the worth band the brand has earned.

Price-Pack Architecture

Is the ladder working?

It audits the pack ladder against potency ratios and pack-size norms, raising the base before touching the larger packs.

Elasticity-Based Simulator

How much can I move?

It sizes every recommendation against modeled own-price elasticity with a cross-elasticity guardrail, returning a revenue outcome the committee can defend.

Run in isolation, the four modules produce four overlapping opportunity lists. Run as one sequenced engine, they produce a single ranked, de-duplicated list with elasticity guardrails applied at the recommendation layer. On one pilot market, two brands came back “optimally priced.” A less rigorous tool would have produced false-positive increases. The engine also tells you when not to act.

Why the engine matters as much as the modules

Most pharma pricing tools break because the analysis and the data assembly live in the same workbook. PRISM separates them and enforces reproducibility at three seams. Schema validation at the input seam means bad inputs fail loudly at the boundary, not silently five steps later. Deterministic transforms at the table seam make every output a pure function of the inputs, so a second analyst gets the same answer. Run metadata at the orchestration seam stamps every output with the inputs and the run that produced it. The engine is front-end agnostic: surface it through Excel, Power BI, or Tableau, and the analytics are unchanged.

See PRISM in action

The PRISM workspace, anonymized

Anonymized views of the PRISM workspace. A fictional manufacturer, Aurora Therapeutics, stands in for client data; the modules, layout, and logic are what your team would run.

Module 1

Price/DDD & competitive price analytics

Module 2

Right-to-Price (9-blocker)

Module 3

Pack-price architecture ladder

Module 4

Elasticity scenario simulator

Cross-cut

Pricing vs inflation

Cross-cut

Pricing actions cockpit

Cross-cut

Market white-space

Cross-cut

Executive summary

What the engine surfaced

A four-archetype emerging-markets pilot

Across a four-archetype emerging-markets pilot (high-inflation Latin America, price-controlled APAC, competitive Latin America, and price-sensitive APAC) covering 30 brands and roughly $215M in annualized in-scope revenue:

Who it’s for

Built for the people who defend the price

What commercial leaders say after the build

“Revology Analytics was able to build a robust, easy-to-use, intuitive and automatic Margin Analytics platform tailored for both Sales and Finance/Pricing users in less than three months.”

Vice President, Strategy & Business Development — MedTech company

“They leveraged historical transactional and competitive analyses, and built price elasticity models to identify key trends and insights that drove meaningful actions.”

Sr. Director, Sales Analytics & Operations — leading medical device company

See PRISM against one of your markets.

Bring one market’s data to a working session. We’ll show the DDD-equivalized competitive read and size the price-realization opportunity.

FAQ

Pharmaceutical price optimization, answered

What is DDD-equivalized pricing?

DDD-equivalized pricing compares pharmaceutical prices on a price-per-Defined-Daily-Dose basis rather than by pack or unit price. Because Defined Daily Dose (a WHO standard) normalizes for strength, pack size, and form, it is the only layer where a like-for-like competitive comparison is honest. PRISM automates that equivalization for your brands and competitors alike.

What is price-pack architecture in pharma?

Price-pack architecture is the discipline of setting prices across a brand’s pack ladder (its strengths and pack sizes) so the steps reflect potency ratios and pack-size norms. PRISM audits the ladder for distortions and raises the base before touching the larger packs. That is a common source of recoverable price realization.

What is Right-to-Price in pharmaceutical pricing?

Right-to-Price is a worth-based pricing method that scores the price a brand has earned relative to competitors, then compares that worth band to realized price. PRISM uses the score to surface brands priced below their worth band and to rank increases the committee can defend.

How do you optimize pharmaceutical prices across multiple markets?

PRISM runs four modules (DDD-equivalized competitive pricing, Right-to-Price worth scoring, price-pack architecture, and elasticity) as one reproducible engine, market by market, and returns a single ranked list of defensible price moves with elasticity guardrails applied. The same engine reproduces the same recommendation from the inputs alone.

Is PRISM software we buy?

No. PRISM is a capability Revology co-designs inside your environment and transfers to your team. The engine is front-end agnostic (Excel, Power BI, or Tableau), and there is no recurring license.

How long does PRISM take to stand up?

A typical PRISM build runs 90–120 days, stood up market by market so your first market returns a ranked, defensible list of price moves before the next one onboards. Capability transfer to your team happens continuously, not at the end of the engagement.

How is a PRISM engagement structured?

As a fixed-scope build, not a subscription. We define the markets and brands in scope at a working session, price the build to that scope, and transfer capability to your analysts throughout. There is no recurring license; your team owns the engine and its outputs at handoff.

Does Revology always use AI?

No, and that is deliberate. AI is a strategic enabler, not the product. When your data and operational readiness support it, we deploy advanced machine learning and agentic AI. When a simpler method reaches the goal faster, we use that and sequence the AI for when it earns its place.

Has Revology been independently ranked?

Yes. Revology Analytics is ranked #1 by PeekWire in “Best Revenue Growth Management Consulting Firms for Mid-Market Companies,” April 2026, recognized for hands-on execution in pricing, sales and marketing AI enablement, and commercial analytics transformation, and for embedding senior experts directly into the client’s team. Read the full ranking.

Industry

Pharmaceutical→

Whitepaper

PRISM: the pharma pricing engine→

Event

AI-Enabled Commercial Analytics & Automation: Build It Yourself, with AI

Pharma pricing leaders own a workbook they quietly mistrust.